| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 24,380 | 32,200 | 62,110 | 30,950 | 28,110 |
| Sales Growth | -24.29% | -48.16% | +100.68% | +10.10% | +8.83% |
| Net Income | -15,160 | -140,780 | -59,800 | -32,610 | -19,710 |
| Net Income Growth | +89.23% | -135.42% | -83.38% | -65.45% | +25.79% |
22nd Century Group Inc (XXII)
1.5800 x 1 1.7200 x 3
Post-market by (Cboe BZX)
1.6100 -0.0500 (-3.01%) 03/26/25 [NASDAQ]
1.5800 x 1 1.7200 x 3
Post-market 1.6100 unch (unch) 16:00 ET
for Wed, Mar 26th, 2025
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
Fiscal Year End Date: 12/31